These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

2135 related items for PubMed ID: 24857785

  • 1. Comparison of targeted next-generation sequencing with conventional sequencing for predicting the responsiveness to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy in never-smokers with lung adenocarcinoma.
    Han JY, Kim SH, Lee YS, Lee SY, Hwang JA, Kim JY, Yoon SJ, Lee GK.
    Lung Cancer; 2014 Aug; 85(2):161-7. PubMed ID: 24857785
    [Abstract] [Full Text] [Related]

  • 2. Clinical outcomes of EGFR-TKI treatment and genetic heterogeneity in lung adenocarcinoma patients with EGFR mutations on exons 19 and 21.
    Yu JY, Yu SF, Wang SH, Bai H, Zhao J, An TT, Duan JC, Wang J.
    Chin J Cancer; 2016 Mar 21; 35():30. PubMed ID: 27001083
    [Abstract] [Full Text] [Related]

  • 3. Picoliter-Droplet Digital Polymerase Chain Reaction-Based Analysis of Cell-Free Plasma DNA to Assess EGFR Mutations in Lung Adenocarcinoma That Confer Resistance to Tyrosine-Kinase Inhibitors.
    Seki Y, Fujiwara Y, Kohno T, Takai E, Sunami K, Goto Y, Horinouchi H, Kanda S, Nokihara H, Watanabe S, Ichikawa H, Yamamoto N, Kuwano K, Ohe Y.
    Oncologist; 2016 Feb 21; 21(2):156-64. PubMed ID: 26768482
    [Abstract] [Full Text] [Related]

  • 4. Are exon 19 deletions and L858R different in early stage lung adenocarcinoma?
    Zhang Y, Ma Y, Li Y, Shen X, Yu Y, Pan Y, Zhang Y, Yu S, Zheng D, Zhao Y, Hu H, Sun Y, Zhang Y, Xiang J, Chen H.
    J Cancer Res Clin Oncol; 2018 Jan 21; 144(1):165-171. PubMed ID: 29026990
    [Abstract] [Full Text] [Related]

  • 5. Next-generation sequencing of tissue and circulating tumor DNA: Resistance mechanisms to EGFR targeted therapy in a cohort of patients with advanced non-small cell lung cancer.
    Zhang Y, Xiong L, Xie F, Zheng X, Li Y, Zhu L, Sun J.
    Cancer Med; 2021 Jul 21; 10(14):4697-4709. PubMed ID: 34173341
    [Abstract] [Full Text] [Related]

  • 6. Audit of Molecular Mechanisms of Primary and Secondary Resistance to Various Generations of Tyrosine Kinase Inhibitors in Known Epidermal Growth Factor Receptor-Mutant Non-small Cell Lung Cancer Patients in a Tertiary Centre.
    Suryavanshi M, Jaipuria J, Mattoo S, Dhandha S, Khatri M.
    Clin Oncol (R Coll Radiol); 2022 Nov 21; 34(11):e451-e462. PubMed ID: 35810049
    [Abstract] [Full Text] [Related]

  • 7. Impact of cigarette smoking on response to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors in lung adenocarcinoma with activating EGFR mutations.
    Kim MH, Kim HR, Cho BC, Bae MK, Kim EY, Lee CY, Lee JS, Kang DR, Kim JH.
    Lung Cancer; 2014 May 21; 84(2):196-202. PubMed ID: 24629638
    [Abstract] [Full Text] [Related]

  • 8. Management and future directions in non-small cell lung cancer with known activating mutations.
    Gerber DE, Gandhi L, Costa DB.
    Am Soc Clin Oncol Educ Book; 2014 May 21; ():e353-65. PubMed ID: 24857124
    [Abstract] [Full Text] [Related]

  • 9. Detection and comparison of peptide nucleic acid-mediated real-time polymerase chain reaction clamping and direct gene sequencing for epidermal growth factor receptor mutations in patients with non-small cell lung cancer.
    Kim HJ, Lee KY, Kim YC, Kim KS, Lee SY, Jang TW, Lee MK, Shin KC, Lee GH, Lee JC, Lee JE, Kim SY.
    Lung Cancer; 2012 Mar 21; 75(3):321-5. PubMed ID: 21930325
    [Abstract] [Full Text] [Related]

  • 10. Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer.
    Ludovini V, Bianconi F, Pistola L, Chiari R, Minotti V, Colella R, Giuffrida D, Tofanetti FR, Siggillino A, Flacco A, Baldelli E, Iacono D, Mameli MG, Cavaliere A, Crinò L.
    J Thorac Oncol; 2011 Apr 21; 6(4):707-15. PubMed ID: 21258250
    [Abstract] [Full Text] [Related]

  • 11. Prediction for response duration to epidermal growth factor receptor-tyrosine kinase inhibitors in EGFR mutated never smoker lung adenocarcinoma.
    Kim HR, Cho BC, Shim HS, Lim SM, Kim SK, Chang J, Kim DJ, Kim JH.
    Lung Cancer; 2014 Mar 21; 83(3):374-82. PubMed ID: 24468202
    [Abstract] [Full Text] [Related]

  • 12. Clinical Outcome of ALK-Positive Non-Small Cell Lung Cancer (NSCLC) Patients with De Novo EGFR or KRAS Co-Mutations Receiving Tyrosine Kinase Inhibitors (TKIs).
    Schmid S, Gautschi O, Rothschild S, Mark M, Froesch P, Klingbiel D, Reichegger H, Jochum W, Diebold J, Früh M.
    J Thorac Oncol; 2017 Apr 21; 12(4):681-688. PubMed ID: 28007627
    [Abstract] [Full Text] [Related]

  • 13. A multicenter blinded study evaluating EGFR and KRAS mutation testing methods in the clinical non-small cell lung cancer setting--IFCT/ERMETIC2 Project Part 1: Comparison of testing methods in 20 French molecular genetic National Cancer Institute platforms.
    Beau-Faller M, Blons H, Domerg C, Gajda D, Richard N, Escande F, Solassol J, Denis MG, Cayre A, Nanni-Metellus I, Olschwang S, Lizard S, Piard F, Pretet JL, de Fraipont F, Bièche I, de Cremoux P, Rouquette I, Bringuier PP, Mosser J, Legrain M, Voegeli AC, Saulnier P, Morin F, Pignon JP, Zalcman G, Cadranel J.
    J Mol Diagn; 2014 Jan 21; 16(1):45-55. PubMed ID: 24183959
    [Abstract] [Full Text] [Related]

  • 14. Comparison of therapeutic effects of EGFR-tyrosine kinase inhibitors on 19Del and L858R mutations in advanced lung adenocarcinoma and effect on cellular immune function.
    Zhou J, Ben S.
    Thorac Cancer; 2018 Feb 21; 9(2):228-233. PubMed ID: 29222872
    [Abstract] [Full Text] [Related]

  • 15. A Phase II Study of Poziotinib in Patients with Epidermal Growth Factor Receptor (EGFR)-Mutant Lung Adenocarcinoma Who Have Acquired Resistance to EGFR-Tyrosine Kinase Inhibitors.
    Han JY, Lee KH, Kim SW, Min YJ, Cho E, Lee Y, Lee SH, Kim HY, Lee GK, Nam BH, Han H, Jung J, Lee JS.
    Cancer Res Treat; 2017 Jan 21; 49(1):10-19. PubMed ID: 27188206
    [Abstract] [Full Text] [Related]

  • 16. Impact of Concurrent PIK3CA Mutations on Response to EGFR Tyrosine Kinase Inhibition in EGFR-Mutant Lung Cancers and on Prognosis in Oncogene-Driven Lung Adenocarcinomas.
    Eng J, Woo KM, Sima CS, Plodkowski A, Hellmann MD, Chaft JE, Kris MG, Arcila ME, Ladanyi M, Drilon A.
    J Thorac Oncol; 2015 Dec 21; 10(12):1713-9. PubMed ID: 26334752
    [Abstract] [Full Text] [Related]

  • 17. Targeted sequencing identifies genetic alterations that confer primary resistance to EGFR tyrosine kinase inhibitor (Korean Lung Cancer Consortium).
    Lim SM, Kim HR, Cho EK, Min YJ, Ahn JS, Ahn MJ, Park K, Cho BC, Lee JH, Jeong HC, Kim EK, Kim JH.
    Oncotarget; 2016 Jun 14; 7(24):36311-36320. PubMed ID: 27121209
    [Abstract] [Full Text] [Related]

  • 18. Comparison of clinical outcomes following gefitinib and erlotinib treatment in non-small-cell lung cancer patients harboring an epidermal growth factor receptor mutation in either exon 19 or 21.
    Lim SH, Lee JY, Sun JM, Ahn JS, Park K, Ahn MJ.
    J Thorac Oncol; 2014 Apr 14; 9(4):506-11. PubMed ID: 24736073
    [Abstract] [Full Text] [Related]

  • 19. Concomitant ALK translocation and EGFR mutation in lung cancer: a comparison of direct sequencing and sensitive assays and the impact on responsiveness to tyrosine kinase inhibitor.
    Won JK, Keam B, Koh J, Cho HJ, Jeon YK, Kim TM, Lee SH, Lee DS, Kim DW, Chung DH.
    Ann Oncol; 2015 Feb 14; 26(2):348-54. PubMed ID: 25403583
    [Abstract] [Full Text] [Related]

  • 20. Monitoring of cyclooxygenase-2 levels can predict EGFR mutations and the efficacy of EGFR-TKI in patients with lung adenocarcinoma.
    Li H, Wang Y, Su F, Li J, Gong P.
    Int J Clin Exp Pathol; 2015 Feb 14; 8(5):5577-83. PubMed ID: 26191267
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 107.